FindTrial
Sign In

Assessment of Liver Stiffness in non- obese patient with type 2 diabetes

Assessment of hepatic fibrosis in non- obese patient with type 2 diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/06/054199
Enrollment
100
Registered
2023-06-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with T2DM (up to 15 years Duration) 2. Age 25 to 60 years 3. BMI 4. Gender- Both 5. USG finding showing definitive fatty liver

Exclusion criteria

Exclusion criteria: 1. Chronic significant alcohol intake ( > 20 gm/day) 2. BMI > 25 kg/m² 3. Congestive heart disease 4. Positive hepatitis B or hepatitis C, secondary causes of fatty liver (eg, consumption of amiodarone and tamoxifen) and congestive hepatopathy. 5. Severe end organ damage or chronic diseases: renal/hepatic failure, any malignancy, major systemic illness etc.

Design outcomes

Primary

MeasureTime frame
To asses hepatic fat (by CAP) and hepatic fibrosis (by kPA) in Non obese patient with T2DM.Timepoint: 6 months—

Secondary

MeasureTime frame
To assess Liver fibrosis in non-obese type 2 diabetes patientsTimepoint: 6 months—

Countries

India

Contacts

Public ContactDr ANOOP MISRA

Fortis CDOC Hospital

anoopmisra@gmail.com01149101222

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026